{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:56:52Z","timestamp":1764403012535,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41409-020-01075-y","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T12:02:46Z","timestamp":1602504166000},"page":"655-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party\u2014EBMT"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-8617","authenticated-orcid":false,"given":"Leyre","family":"Bento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Finel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Khvedelidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Fegueux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gramatzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tsoulkani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Nati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"1075_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong T-C, Prince HM, et al. Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197\u2013203.","journal-title":"J Clin Oncol"},{"key":"1075_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3324\/haematol.2012.069393","volume":"98","author":"A Gibb","year":"2013","unstructured":"Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98:611\u20134.","journal-title":"Haematologica"},{"key":"1075_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.12120","volume":"160","author":"G Corazzelli","year":"2013","unstructured":"Corazzelli G, Angrilli F, D\u2019Arco A, Ferrara F, Musto P, Guarini A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207\u201315.","journal-title":"Br J Haematol"},{"key":"1075_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/bjh.12821","volume":"166","author":"A Anastasia","year":"2014","unstructured":"Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166:140\u20132.","journal-title":"Br J Haematol"},{"key":"1075_CR6","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"1075_CR7","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","volume":"115","author":"B Sarina","year":"2010","unstructured":"Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671\u20137.","journal-title":"Blood"},{"key":"1075_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/bmt.2012.116","volume":"48","author":"R Crocchiolo","year":"2013","unstructured":"Crocchiolo R, Castagna L, F\u00fcrst S, El-Cheikh J, Faucher C, Oudin C, et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2013;48:249\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"1075_CR9","first-page":"612","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Annals of oncology: official journal of the European Society for. Med Oncol. 2019;30:612\u201320.","journal-title":"Med Oncol"},{"key":"1075_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"1075_CR11","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood"},{"key":"1075_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bmt.1702796","volume":"27","author":"HM Lazarus","year":"2001","unstructured":"Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, et al. Autotransplants for Hodgkin\u2019s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001;27:387\u201396.","journal-title":"Bone Marrow Transplant"},{"key":"1075_CR13","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531\u20133.","journal-title":"Leuk Lymphoma"},{"key":"1075_CR14","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","volume":"18","author":"AM Carella","year":"2000","unstructured":"Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2000;18:3918\u201324.","journal-title":"J Clin Oncol"},{"key":"1075_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/bmt.2014.304","volume":"50","author":"L Castagna","year":"2015","unstructured":"Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, et al. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant. 2015;50:499\u2013504.","journal-title":"Bone Marrow Transplant"},{"key":"1075_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41409-017-0032-1","volume":"53","author":"J Mariotti","year":"2018","unstructured":"Mariotti J, Bramanti S, Devillier R, Furst S, El Cheikh J, Sarina B, et al. Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. Bone Marrow Transplant. 2018;53:366\u201370.","journal-title":"Bone Marrow Transplant"},{"key":"1075_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"1075_CR18","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1075_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"1075_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/leu.2011.230","volume":"26","author":"TH Terwey","year":"2012","unstructured":"Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2012;26:536\u201342.","journal-title":"Leukemia"},{"key":"1075_CR21","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Brice P, Ferm\u00e9 C, Divin\u00e9 M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin\u2019s lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group. J Clin Oncol. 2008;26:5980\u20137.","journal-title":"J Clin Oncol"},{"key":"1075_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bjh.15184","volume":"181","author":"B Deau","year":"2018","unstructured":"Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, et al. Tandem haematopoietic stem cell transplantation for high risk relapsed\/refractory Hodgkin lymphoma: a LYSA study. Br J Haematol. 2018;181:341\u20139.","journal-title":"Br J Haematol"},{"key":"1075_CR23","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","volume":"119","author":"R Chen","year":"2012","unstructured":"Chen R, Palmer JM, Thomas SH, Tsai N-C, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119:6379\u201381.","journal-title":"Blood"},{"key":"1075_CR24","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase ii checkmate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol"},{"key":"1075_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","journal-title":"N Engl J Med"},{"key":"1075_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen Y-B, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22\u20139.","journal-title":"Blood"},{"key":"1075_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40\u20138.","journal-title":"Blood"},{"key":"1075_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","volume":"5","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance therapies for hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715\u201322.","journal-title":"JAMA Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01075-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T23:55:09Z","timestamp":1633996509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01075-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01075-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors do not report any conflict of interest in the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}